{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:34:14Z","timestamp":1787567654058,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation\u2014Flanders (FWO) through a Fundamental Clinical Mandate (FKM) awarded to Nouredin Messaoudi","doi-asserted-by":"publisher","award":["1801425B"],"award-info":[{"award-number":["1801425B"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Transcriptomic profiling reproducibly resolves pancreatic ductal adenocarcinoma (PDAC) into two prognostically divergent tumour-intrinsic programmes\u2014classical\/progenitor and basal-like\/squamous\u2014accompanied by a separable stromal axis; additional proposed classes are strongly influenced by low tumour cellularity and generalise poorly across datasets. Rather than cataloguing these programmes, this review synthesises evidence that they behave as plastic cell states and proposes an integrative developmental framework for interpreting that plasticity, rather than claiming its discovery. The framework combines a normal-pancreas developmental reference frame, the regulation of state by lineage transcription factors, epigenetic remodelling, oncogenic (KRAS) dosage, stromal instruction, and treatment pressure, and a testable notion of spatial disorganisation. Throughout, we separate robust prognostic evidence\u2014basal-like assignment and low GATA6 expression are consistently associated with worse outcome\u2014from predictive claims: predictive utility remains unproven because no completed prospective trial has assigned treatment according to classical\u2013basal subtype and demonstrated improved clinical outcome from that strategy, and existing signals derive from retrospective or observational analyses. The proposition that the classical\u2013basal spectrum reflects a spatially disordered redeployment of the normal duct\u2019s luminal\u2013basal hierarchy is presented as a hypothesis requiring validation in independent atlases rather than as established biology. We define the falsifiable experiments needed to test the framework and its clinical implications.<\/jats:p>","DOI":"10.3390\/cancers18172733","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:20:02Z","timestamp":1787563202000},"page":"2733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Classical\u2013Basal Spectrum in Pancreatic Ductal Adenocarcinoma: A Developmental Framework for Tumour Cell Plasticity and Clinical Translation"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0230-662X","authenticated-orcid":false,"given":"Ikra","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzadinne","family":"Belhaj","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8982-5416","authenticated-orcid":false,"given":"Alessandro","family":"Gemini","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza Azra","family":"Ibis","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3207-3982","authenticated-orcid":false,"given":"Nouman","family":"Darsif","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najoua","family":"Rouani","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4457-4255","authenticated-orcid":false,"given":"Aude","family":"Vanlander","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-2604","authenticated-orcid":false,"given":"Nouredin","family":"Messaoudi","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features","volume":"155","author":"Puleo","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Kim","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","article-title":"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer","volume":"26","author":"Rashid","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"zcac030","DOI":"10.1093\/narcan\/zcac030","article-title":"The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping","volume":"4","author":"Lautizi","year":"2022","journal-title":"NAR Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/s41467-021-26059-4","article-title":"Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy","volume":"12","author":"Krieger","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","article-title":"Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity","volume":"83","author":"Williams","year":"2023","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.celrep.2018.10.051","article-title":"TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma","volume":"25","author":"Somerville","year":"2018","journal-title":"Cell Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","article-title":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","volume":"1","author":"Hayashi","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gutjnl-2020-321397","article-title":"A GATA6-centred gene regulatory network involving HNFs and \u0394Np63 controls plasticity and immune escape in pancreatic cancer","volume":"71","author":"Kloesch","year":"2022","journal-title":"Gut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3753","article-title":"Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis","volume":"49","author":"McDonald","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","article-title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes","volume":"554","author":"Mueller","year":"2018","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer","volume":"26","author":"Jang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","article-title":"Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial","volume":"16","author":"Knox","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/path.6212","article-title":"High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer","volume":"262","author":"Michiels","year":"2024","journal-title":"J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/2159-8290.CD-20-0633","article-title":"Cell of Origin Influences Pancreatic Cancer Subtype","volume":"11","author":"Flowers","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/2159-8290.CD-20-1202","article-title":"Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin","volume":"11","author":"Espinet","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jcmgh.2021.11.010","article-title":"On the Origin of Pancreatic Cancer: Molecular Tumor Subtypes in Perspective of Exocrine Cell Plasticity","volume":"13","author":"Backx","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_27","first-page":"337970","article-title":"Luminal-basal stratification of the native human pancreatic duct is differentially represented in pancreatic cancers","volume":"2025","author":"Michiels","year":"2026","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2020-322874","article-title":"Discovery and 3D imaging of a novel \u0394Np63-expressing basal cell type in human pancreatic ducts with implications in disease","volume":"71","author":"Martens","year":"2021","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41586-025-08927-x","article-title":"Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer","volume":"642","author":"Pei","year":"2025","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1158\/1078-0432.CCR-20-4712","article-title":"Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies","volume":"27","author":"Guo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Biffi","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Carstens","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.xcrm.2024.101557","article-title":"GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery","volume":"5","author":"Real","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/gutjnl-2023-330480","article-title":"Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer","volume":"73","author":"Mustafa","year":"2024","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41416-025-03274-0","article-title":"Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy","volume":"134","author":"Bouchart","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.22.02668","article-title":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial","volume":"42","author":"Nicolle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine\/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.ebiom.2020.102858","article-title":"Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer","volume":"57","author":"Nicolle","year":"2020","journal-title":"eBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14951","DOI":"10.1038\/s41598-021-94544-3","article-title":"The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer","volume":"11","author":"Duan","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS (G12D) Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS (G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15598","DOI":"10.1038\/s41598-024-65900-w","article-title":"Combination immunohistochemistry for CK5\/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-na\u00efve pancreatic ductal adenocarcinoma","volume":"14","author":"Shibayama","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hpb.2024.02.001","article-title":"Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: A systematic review","volume":"26","author":"Robertson","year":"2024","journal-title":"HPB"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","article-title":"hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma","volume":"28","author":"Perera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pan.2024.01.009","article-title":"The prognostic and predictive role of class III \u03b2-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma","volume":"24","author":"Sahin","year":"2024","journal-title":"Pancreatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:32:03Z","timestamp":1787563923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172733"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172733","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}